Pristiq Extended-Release (DESVENLAFAXINE SUCCINATE)
Pristiq Extended-Release (DESVENLAFAXINE SUCCINATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Pristiq Extended-Release; Generic name: DESVENLAFAXINE SUCCINATE; Manufacturer: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
| Brand name | Pristiq Extended-Release |
|---|---|
| Generic name | DESVENLAFAXINE SUCCINATE |
| Manufacturer | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| Used for | 1 INDICATIONS AND USAGE PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ). |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Recommended dose: 50 mg once daily with or without food ( 2.1 ). • There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). • The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). • Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). • Take tablets whole; do not divide, crush, chew, or dissolve ( 2. |
| Warnings | WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) ] . In patients of all ages who are started on antidepressant therapy, |
| Active ingredient(s) | DESVENLAFAXINE SUCCINATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce |